Showing results (91-100 of 204) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
Blood Neoplasia|June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomasPaola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood|October 21, 2018
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapyShigeru Kusumoto, Luca Arcaini, Xiaonan Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphomaJohn Gerecitano, Carol Portlock, Paul Hamlin, et al.
Haematologica|December 3, 2011
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtypeWyndham H Wilson, Sin-Ho Jung, Pierluigi Porcu, et al.
Blood|December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphomaCraig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaParastoo B Dahi, Roni Tamari, Sean M Devlin, et al.
Cancer|August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes projectAndrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Pageof 21